Central Action of Botulinum Toxin Type A - Is It Possible?

被引:1
|
作者
Galazka, M. [1 ]
Soszynski, D. [1 ]
Dmitruk, K. [2 ]
机构
[1] Nicholas Copernicus Univ, Ludwik Rydygier Coll Med, Dept Physiol, Neuroimmunol Unit, Bydgoszcz, Poland
[2] Nicholas Copernicus Univ, Ludwik Rydygier Coll Med, Human Physiol Unit, Bydgoszcz, Poland
关键词
botulinum toxin (BoTx); proteins of the SNARE complex; neurotransmitters; effeects on the CNS; anterograde transport; antinociceptive effect; NEUROTOXIN TYPE-A; CENTRAL-NERVOUS-SYSTEM; CERVICAL DYSTONIA; FOCAL DYSTONIA; TETANUS TOXIN; RAT MODEL; MUSCLE; INJECTION; RELEASE; PAIN;
D O I
10.1007/s11062-015-9540-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Botulinum toxin (BoTx) is a product of gram-positive anaerobic bacteria of the Clostridium genus. At present, seven serotypes (A to G) of BoTx have been identified. Each of them functions as a zincdependent endopeptidase that hydrolyzes peptide bonds within soluble N-ethylmaleimide-sensitive factor attaching protein receptors. BoTx affects proteins required for neurotransmitter release through presynaptic membranes. As a result, muscle weakness develops, or complete paralysis of the muscles occurs. These effects are not only limited to striated muscles but also may have impact on smooth muscles and secretory glands. The observation that BoTx can diffuse from the site of administration may indicate the possibility of direct or indirect influence of the toxin on the CNS. Consequently, the question arises: What is the mechanism of the central action of BoTx? Several mechanisms of such action have been proposed. However, recent findings showed that the most probable mechanism responsible for the central effects of BoTx action is its anterograde transport. In this review, we describe and discuss the most important aspects related to BoTx action on the CNS.
引用
收藏
页码:326 / 336
页数:11
相关论文
共 50 条
  • [41] Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy
    Luvisetto, Siro
    TOXINS, 2021, 13 (11)
  • [42] Immunogenicity of botulinum toxin
    Wee, Syeo Young
    Park, Eun Soo
    ARCHIVES OF PLASTIC SURGERY-APS, 2022, 49 (01): : 12 - 18
  • [43] Botulinum Toxin Type A: Adverse Events and Management
    Cavallini, Maurizio
    Papagni, Marco
    Lazzari, Riccardo
    Santorelli, Adriano
    FACIAL PLASTIC SURGERY, 2022, 38 (02) : 111 - 115
  • [44] Treatment of spasticity with injections of botulinum toxin type A
    Wissel, J.
    Mueller, J.
    NERVENHEILKUNDE, 2013, 32 (12) : 933 - 938
  • [45] Botulinum Toxin in the Ophthalmology
    Wabbels, Bettina
    AUGENHEILKUNDE UP2DATE, 2019, 9 (02) : 183 - 194
  • [46] Treatment of congenital esotropia with botulinum toxin type A
    Baggesen, Kirsten
    Arnljot, Havard Magnus
    ACTA OPHTHALMOLOGICA, 2011, 89 (05) : 484 - 488
  • [47] THE ROLE OF BOTULINUM TOXIN TYPE A IN TRIGEMINAL NEURALGIA
    Guimaraes, Bruno
    Aguiar-Branco, Catarina
    Camoes-Barbosa, Alexandre
    TOXICON, 2021, 190 : S29 - S30
  • [48] Treatment of a Painful Keloid with Botulinum Toxin Type A
    Uyesugi, Betty
    Lippincott, Benjamin
    Dave, Shashank
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2010, 89 (02) : 153 - 155
  • [49] Botulinum toxin type A for the treatment of inverse psoriasis
    Zanchi, M.
    Favot, F.
    Bizzarini, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (08) : 955 - 956
  • [50] Using botulinum toxin for pelvic indications in women
    Rao, Archana
    Abbott, Jason
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2009, 49 (04) : 352 - 357